Press Releases

11-04-09 NovaRx Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix^® Study

05-08-09 Lucanix featured on MSN Health

04-15-09 NCI’s SBIR and STTR Programs Feature NovaRx as Key Success Story

12-29-08 Serbia First in Europe to Participate in Phase III Trial of Lung Cancer Vaccine

12-10-08 Lung Cancer Vaccine Giving Patients New Hope

08-22-08 Vaccine Strong in Tests

08-21-08 Lung Cancer Vaccine Shows Great Promise

08-21-08 NovaRx Moves into Phase III with Cancer Vaccine Lucanix

08-21-08 NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients

05-01-08 NovaRx Selects ISI’s eCTDXPress and ISIWriter

06-09-06 Tiny NovaRx Getting Noticed

06-05-06 Lucanix Phase II Clinical Data Demonstrates Significantly Increased Survival in Lung Cancer Patients

05-31-06 NovaRx To Present Lucanix^® Phase II Clinical Data at ASCO

09-08-04 The Immune Response Corporation and NovaRx Corporation Announce Revision of Licensing Agreement for Cancer Cell Line Vaccines

05-18-04 NovaRx Achieves Full Enrollment of its Phase II Clinical Trial in Non-Small Cell Lung Cancer Ahead of Schedule

05.12.04 NovaRx Announces $2.2 million Award of SBIR Grant to Help Fund its Pivotal Phase II/III Clinical Trial in Brain Cancer